Model N positions itself for coming revisions in pharma trade practices
Model N made its bones with the concept of revenue management: in life sciences, analyzing the elements of commercial contracts to maximize profitability and minimizing poorly executed incentive or rebate programs. Now, in a commissioned 2019 survey across its prospect base of life sciences and high tech companies, Model N finds that the top concerns for financial well-being are:
Especially in the current era of intense questioning of the life sciences practices in working with PBMs and other intermediaries, revenue leakage is a key priority. “It makes perfect sense why this is so important,” says Jason Blessing, Model N CEO. “Revenue leakage, often from incentive overpayments, reduces top line revenue and negatively impacts margins.”
The survey, announced at the company’s annual Rainmaker Conference (Miami Beach, March 11-13), has recommendations based on what top-performing companies are doing to maximize revenue and minimize leakage and compliance problems:
The full survey is available for download at Model N's website.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.